Blue­bird bio com­pletes split in­to two com­pa­nies; BeiGene builds out Brukin­sa da­ta at ASH

Blue­bird bio has been of­fi­cial­ly split in half.

Both sides of the once-sin­gu­lar cell and gene ther­a­py com­pa­ny an­nounced Thurs­day they have com­plet­ed their split …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.